摘要
目的:探讨赖诺普利对血压正常的早期糖尿病肾病患者的尿蛋白的控制疗效及安全性。方法:94例血压正常早期糖尿病肾病患者,将血糖控制稳定后分为两组,两组间各参数无显著性差异;A组47例为赖诺普利治疗组,口服赖诺普利l0 m g,1次/d;B组47例为对照组,服用保肾康。观察治疗0,3,6,12,24个月,尿蛋白量,平均动脉压,肝、肾功能,血糖,血脂及电解质。结果:A组治疗3月后,尿蛋白量与治疗前及B组比较均有显著差异(P<0.05)。治疗24个月后,肾功能无恶化。结论:赖诺普利是对血压正常的早期糖尿病肾病患者能确实降低尿蛋白,保护肾功能的安全药物。
Objective To investigate the effect and the safety of lisinopril for controlling the urinary protein in early diabetic nephropathy patients. Methods Ninety-four early diabetic ＇nephropathy patients with normal blood pressure were divided into two groups after their blood sugar were controlled into stability. And the data has no significant difference between the two groups. Group A （47 cases） took lisinopril, 10 mg/d; While group B（47 cases） took Baoshenkang tablets. The quantity of urinary protein, the average artery pressure, the function of liver and kidney, the blood sugar, the blood fat and electrolyte were determined after treatment of 0, 3, 12, 24 months. Results The urinary protein＇s quantity of group A after the treatment of 3 months had a significant difference with the condition before the treatment and the urinary protein＇s quantity of group B （P〈 0. 05）. Conclusion Lisinopri is a safe medicine, which can reduce the quantity of urinary protein of early diabetic nephropathy patients with normal blood pressure.
出处
《实用诊断与治疗杂志》
2006年第4期253-254,257,共3页
Journal of Practical Diagnosis and Therapy
关键词
糖尿病肾病
尿蛋白
Diabetic nephropathy
urinary protein
